-
A1 vs AMD3100 in Colorectal Cancer
2026-09-20
The reference study evaluates A1, a fluorinated CXCR4 inhibitor, against AMD3100 across computational, cellular, and mouse colorectal cancer models. A1 showed stronger predicted CXCR4 binding, reduced CT-26 proliferation and migration, altered immunosuppressive tumor-microenvironment signals, and improved tumor control relative to AMD3100, although substantial validation remains necessary.
-
Dimetridazole: Mechanism, Assays, and Limits
2026-09-19
Dimetridazole, also called 1,2-Dimethyl-5-nitroimidazole, is a nitroimidazole research compound for studying anaerobic bacteria, protozoa, quorum sensing, and antimicrobial combinations. Its environmental oxidation is chemically rapid under hydroxyl-radical conditions, but transformation products can retain toxicity, so assay interpretation requires both biological and analytical controls.
-
IDH2 Reprogramming and HIF-1α in Colorectal Cancer
2026-09-18
The reference study identifies IDH2 as a metabolic driver of colorectal cancer progression, linking reductive citrate-cycle activity to mitochondrial ATP production, glycolysis, and HIF-1α signaling. Its combined genetic, pharmacological, metabolic, and in vivo design provides a framework for testing whether α-ketoglutarate availability is a causal regulator rather than a passive metabolic readout.
-
Polymyxin B Sulfate in Resistance Research
2026-09-18
Polymyxin B sulfate adds a functional membrane-stress readout to workflows that already measure carbapenemase genes, plasmid transfer, and clonal spread. This guide shows how to integrate the compound into Gram-negative infection research, dendritic cell assays, and sepsis-model planning without confusing phenotypic activity with genotype-specific evidence.
-
SR-202: A Practical PPARγ Antagonist Workflow
2026-09-17
Use SR-202 to separate PPARγ-dependent transcription from downstream metabolic and inflammatory effects in adipocyte and macrophage models. This workflow translates recent PPARγ/STAT pathway findings into practical assay design, controls, and troubleshooting for insulin resistance research, obesity research, and type 2 diabetes research.
-
Tunable Human Intestinal Organoids and GSK-3 Control
2026-09-17
This Nature Communications study develops a small-molecule strategy for maintaining high proliferation while expanding cellular diversity in human small intestinal organoids. Its reversible and directional control of lineage output offers a practical framework for scalable organoid culture, although the system remains an in vitro model that requires context-specific validation.
-
TPPU: Practical sEH Inhibition Workflows
2026-09-16
TPPU is a nanomolar soluble epoxide hydrolase inhibitor for connecting fatty acid epoxide signaling with inflammatory pain, redox biology, and bone research. This workflow-focused guide covers formulation, lipid mediator assays, osteoclast experiments, controls, and troubleshooting for more reproducible sEH studies.
-
A1 CXCR4 Inhibition in Colorectal Cancer
2026-09-16
Khorramdelazad et al. evaluated the fluorinated CXCR4 inhibitor A1 across molecular modeling, CT-26 cell assays, and a murine colorectal cancer model, using AMD3100 as a comparator. A1 showed stronger predicted receptor binding, reduced tumor-cell proliferation and migration, altered immunosuppressive tumor-microenvironment signals, and improved tumor control and survival in vivo, although further validation is needed before clinical translation.
-
PLPP1, Z-Ligustilide, and Cisplatin Resistance
2026-09-15
This preprint links the activity of Z-ligustilide plus cisplatin to PLPP1-associated phospholipid remodeling, reduced PIP3–AKT signaling, cell-cycle arrest, and apoptosis in cisplatin-resistant lung cancer cells. Its integrated metabolomics, transcriptomics, functional knockdown, and clinical-dataset analyses suggest a mechanistic framework for studying lipid metabolism in cisplatin resistance, while the preclinical design requires validation beyond the tested cell models.
-
Gut Microbiota, RPE/Choroid, and AMD Transcriptomics
2026-09-15
Zhang and colleagues show that the absence of gut microbiota is associated with distinct RPE/choroid gene-expression changes and reduced laser-induced choroidal neovascularization in mice. The study provides experimental support for a gut–RPE/choroidal axis in AMD-related biology while also highlighting the need to distinguish microbiota-associated effects from model-specific and tissue-collection factors.
-
Bifendate Attenuates Hepatic Steatosis in Mice
2026-09-14
The reference study showed that Bifendate selectively reduced hepatic cholesterol and triglyceride accumulation in several mouse models of diet- and cholesterol-induced hypercholesterolemia. Its key contribution was to distinguish liver lipid lowering from systemic serum lipid reduction, providing a focused preclinical rationale for studying DDB as a hepatoprotection agent and lipid metabolism regulator.
-
Calcitriol B2141 for Reliable Cell Assays
2026-09-14
Learn how Calcitriol (SKU B2141), the active metabolite of vitamin D3, can support more interpretable proliferation, viability, differentiation, and immune-modulation experiments. This scenario-driven guide covers assay interpretation, solvent handling, endometrial models, cytokine studies, and practical vendor-selection criteria.
-
C8-HSL Drives Lung Cancer Cell Aggressiveness
2026-09-13
A 2026 FASEB Journal study identifies the bacterial quorum-sensing molecule C8-HSL as a potential mediator between lung microbiota and malignant behavior. Using H460 lung cancer models, the researchers linked C8-HSL exposure to increased proliferation, migration, and invasion through PI3K/AKT/ERK activation and associated changes in cell-cycle and epithelial–mesenchymal markers.
-
EGCG Nanoparticles Intensify FLASH-RT Responses
2026-09-12
Xu and colleagues developed functionalized self-assembled EGCG nanoparticles, termed BENPs, to address the limited tumor-control advantage of FLASH radiotherapy over conventional irradiation. In 4T1 models, BENPs increased radiation-associated oxidative stress and DNA damage, promoted tumor-cell death, and strengthened immune activation while maintaining favorable preliminary safety findings.
-
Plerixafor: A CXCR4 Trafficking Probe
2026-09-11
Plerixafor (AMD3100) is more than a CXCR4 antagonist: it is a useful perturbation tool for separating CXCL12-directed cell trafficking from downstream effector activity. This article translates platelet-extravasation findings into practical assay decisions for cancer, hematopoietic, and inflammatory research.